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SUMMARY.-Pregnancy-dependent mammary tumours in BR6 mice first
appeared during the third week of pregnancy. Regressed tumours reappeared
chiefly during the second week. Alkaline phosphatase activity in normal
mammary tissue indicated a uniform increase in growth during pregnancy with
no marked increase at anyparticular time. Pseudopregnancy was not sufficient
to induce new tumours, though it had some stimulating effect on existing,
regressed ones. 5-Hydroxy-tryptamine did not cause tumours in virgin mice,
but seemed to influence tumour appearance in breeding females. Its possible
mode of action is discussed.
THE BR6 strain of mice was founded by crossing a C57 Black female with an
RIII male (Foulds, 1947, 1949a). All mice carry a mammary tumour virus
presumably derived from the RIII progenitor. Mammary tumour incidence in
breeding females is 94%0, the modal appearance of tumours being in mice about
6 months old and which had had four pregnancies (Mundy and Williams, 1961).
In virgin mice the tumour incidence is 48% but the mean age at which tumours
appear is 89 weeks (S.E. ± 4) and they very seldom appear in virgin mice less than
12 months old. Those tumours arising in breeding females usually appear first
during pregnancy and regress either completely or partially after parturition.
Eventually the tumours continue to grow independently, but initially at least,
growth is stimulated by pregnancy.
This paper describes attempts to find out how important the ovarian influences
ofearly pregnancy are in tumour growth. The first section describes the results of
a survey of the times of tumour appearance during pregnancy. In the next two
experiments mice were made pseudopregnant by pairing them with vasectomised
males, and the effect of this condition on tumour growth was studied.
Growth of the mammary gland is reflected by alkaline phosphatase activity
(Huggins, Mainzek and Briziarelli, 1958) and in the fourth experiment this enzyme
was measured to see ifa normal gland showed a surge in growth at any time during
pregnancy.
An attempt was made to ascertain the minimal duration ofplacental influence
required for tumour development, by terminating each pregnancy at a given time.
A non-hormonal, non-traumatic method was required, and 5-hydroxy-tryptamine
(5HT) was reported by Lindsay, Poulson and Robson (1963) to be effective in mice
by subcutaneous injection. The use of5HT led to an investigation ofthe influence
of this substance itself on tumour development.52ATDREY E. LEE
MATERIALS AND TECHNIQUES
Mice
Breeding mice were housed one pair to a box and left together all the time so
that post-partum mating could take place. Females were allowed to suckle their
litters which were weaned when 1 month old. They had free access to water and
Diet GR25 (Dixon: Ware). The day of finding a vaginal plug was designated
day 1 of pregnancy. Virgin females were housed eight to a box.
Control groups consisted of litter-mates of the treated animals. Mice which
did not develop tumours were kept until they died. Tumours were measured with
calipers twice a week, and the product of two diameters recorded. Following the
nomenclature ofFoulds (1949b), those tumours whichregressed completelybetween
pregnancies were called Type I and those showing only partial regression, Type II.
Vasectomy was carried out through ventral incisions under " Avertin"
anaesthesia.
5-Hydroxy-tryptamine (Serotonin)
5-Hydroxy-tryptamine-creatinine sulphate (5HT) was dissolved in distilled
water to give a concentration of3*0 mg. per 0.1 ml. This was injected subcutane-
ously.
Enzyme assay
Alkaline phosphatase activity in mammary gland tissue was measured by the
following adaptation of the method of King, Haslewood, Delory and Beall (1942)
for plasma phosphatase. The right abdominal gland including the fat pad was
used for the assay. It was weighed wet, then homogenised in a ground glass
homogeniser with pH 10.0 sodium carbonate/bicarbonate buffer so that the final
concentration was 5% (w/v). Two 0-2 ml. aliquots ofthis homogenate were taken
for assay; the second aliquot was placed in a boiling water-bath for 1 minute to
destroy the enzyme activity and served as ablank. The homogenate samples were
incubated with buffer, substrate (M/100 disodium monophenyl phosphate), and
0-005 M magnesium sulphate (Mathies, 1961) for 1 hour at 370 C. The amount of
phenol liberated was measured colorimetrically, as described by King et al. (1942).
EXPERIMENTAL
Time during pregnancy of mamnary tumour development
Fig. 1 shows the number ofnew tumours (that is, those which were palpable for
the first time), and those which started to grow again following regression, plotted
against the days of pregnancy.
Ninety-three per cent ofnew tumours appeared after day 12; the remainder on
days 11 and 12. The mean time of appearance was 17-4 days ± 0 3. When the
group was subdivided, the tumours which subsequently regressed completely after
parturition (Type I) appeared significantly later (P < 0.05) than those showing
incomplete regression (days 18-1 ± 03 and 16-7 ± 0.6).
The second histogram ofFig. 1 shows that 36% ofType I tumours recurred by
day 12, and 64% after day 12, with a mean time ofrecurrence of 13-2 days ± 0 4.
Tumours which had only partially regressed (Type II) resumed growth earlier, as
seen in the third histogram: 66% by day 12, and 34% after this, with a mean of
10-9 days ± 0 4.
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FIG. 1.-Distribution of tumour appearance during pregnancy. Type I tumours are those
which reappear after complete regression and Type I are those which increase in size after
partial regression.
Only three (one Type I and two Type II) of the total of 134 tumours of both
types appeared before day 5, that is before implantation had taken place.
Effect ofpseudopregnancies on regressedpregnancy-dependent mmmary tumours
The distribution of the time of tumour recurrence suggested that pseudo-
pregnancy might provide sufficient hormonal stimulation for the regrowth ofexist-
ing tumours. To test this, 14 females with regressed Type I tumours were paired
with vasectomised males. These females were between 5 and 12 months old, and
hadalreadyhadtwo to ninelitters. Betweenthem they had atotal of21 tumours.
Normally these completely regressed tumours would not be expected to reappear
until the next pregnancy.
During four cycles of pseudopregnancy 12 tumours recurred, 9 did not, and
3 new tumours appeared. There was no significant difference in age or parity
between mice with recurring and non-recurring tumours, and 3 mice had both
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types, supporting the view that the response depends on the state of the tumour
rather than on the state of the host. The tumours which did reappear were pre-
sumably ones which had progressed towards hormone-independence, as only one
showed any cessation of growth at the end of each pseudo-pregnancy. All the
other tumours grew continuously. A similar situation is seen in breeding females
where pregnancy-dependent tumours may eventually become autonomous during
normal breeding. These results indicate that pseudopregnancy may provide a
stimulus to growth once a tumour has been established.
Influence ofpseudopregnancies on mammary tumour development in nulliparous mice
It was found that pseudopregnancies could not replace normal pregnancies in
promoting the early appearance of tumours, by pairing virgin females with
vasectomised males. The 7 females in the experiment were 2 to 3 months old
when paired, and were examined daily for vaginal plugs. For the first 2 months
vaginal smears were taken daily, and the average length ofa pseudopregnancy was
found to be 12 days.
One mouse developed a tumour 37 weeks later which showed a slight decrease
in growth at the ends ofthe next three pseudopregnancy cycles. Five more mice
eventually developed tumours, but not until 59 to 107 weeks after pairing. These
tumours grew continuously and therefore resembled those of virgin females which
are hormone-independent and do not arise until the mice are more than a year old.
The suggestion that pseudopregnancy can stimulate established tumours but
not initiate them is in accordance with the detection ofrecurring tumours earlier in
pregnancy than the appearance of new ones (Fig. 1).
Mammary gland alkaline phosphatase activity
To study the growth of normal mammary glands during pregnancy, alkaline
phosphatase activity was measured. Virgin mice were paired and examined daily
for vaginal plugs. The enzyme was assayed on each day ofpregnancy but results
from two consecutive days have been combined in Fig. 2. Each point is the mean
of 9 to 12 animals. Because of the variable amount of fat in each gland, results
based on the whole gland seemed a more reliable indication ofactivity than ifthey
were expressed per mg. wet weight. The figures have been plotted on a log scale,
andlie on astraight line (regression coefficient, r = 0.98), suggesting anexponential
increase ofenzyme activity. Thehigherlevels inthe second halfofpregnancy may
be a reflection ofthe increased number ofcells in the tissue, and do not necessarily
imply increased hormone stimulation at this time. Munford (1963) found total
alkaline phosphatase activity of the glands increased throughout pregnancy, but
activity/mg. DNA showed little change.
Effect of interrupted pregnancies on mammary tumour induction
The effect oflimiting placental influences was investigated by terminating each
pregnancy during its second week, by means of 5HT injections.
Fifteen virgin mice, 2 to 5 months old, were paired and examined daily for
vaginal plugs; the finding of a plug indicated day 1 of pregnancy. 3.0 mg. 5HT
was injected either on days 10 and 11 (6 mice) or on days 14 and 15 (9 mice),
(Series I in Table I). Unfortunately 5HT was not completely effective in the BR6
strain of mice and some pregnancies continued to term with normal delivery and
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FIG. 2.-Alkaline phosphatase activity in mammary glands of pregnant mice. Each point
represents log (>Lg. phenol liberated/hour/gland), and is the mean of 9 to 12 mice ±S.E.
lactation, sothattheexperiment could notbe completed. However, it seemedthat
the treated mice developed tumours earlier than usual, often during the second
pregnancy, whereas most breeding females do not develop tumours until after four
pregnancies. To confirm this, 5HT was given to further groups of breeding and
virgin females. The results are described in the next section.
5-Hydroxy-tryptamine and tumour development
Ten female mice aged 2 to 6 months were paired, and given two or three daily
doses of 3 0 mg. 5HT, usually during the second week ofeach pregnancy. Sisters
ofthetreated mice formed a control group. They werepaired atthe sametime and
allowed to breed normally. Table I (Series II) shows that there was no difference
in final tumour incidence between the treated and the control animals but in the
former group tumours developed after an average of 1-9pregnancies comparedwith
5*2 in the control group (P < 0.01).
TABLE I.-Tumour Incidence in Mice Given 5-Hydroxytr?yptamine (5HT)
(For injection regime, see text)
Appearance of first tumour
(mean ±s.E.)
No. with AA_-_-_
Status of mice tumours/total Age in weeks Parity
Series I Parous + 5HT . 15/15 . 34±4 2 3±0 6
SeriesII . Parous + 5HT . 8/10 27±2 1-9±0-8*
Parous controls 6/9 34±6 5-2±1.9*
Series III Virgin + 5HT . 13/22 95±5
Virgin controls . 8/18 . 90±7
* Significantly different, P0.001 < 0.01.
A group of virgin mice received two daily injections of 3 0 mg. 5HT approxi-
mately once a month for about a year, starting whenthey were aged 2 to 4 months.
Sisters ofthese mice formed a control group (Series III in Table I). There was no
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difference between the two groups either in tumour incidence or in the age at which
tumours developed.
The results given in Table I show that although there was some indication that
5HT influenced tumour development in breeding mice, it did not affect virgin mice
at the doses used.
DISCUSSION
Geometric growth at a uniform rate throughout pregnancy would result in new
tumours becoming palpable later than ones which had regressed but which still
consisted of small groups of cells. However, tumours often did not appear until
laterthanwouldhavebeenexpectedonthebasisofasteadygrowthrate, suggesting
that their growth was slower during early pregnancy than during the later stages.
The late appearance of new tumours, and the negligible influence of pseudo-
pregnancies suggested that ovarian hormones were not by themselves sufficient to
initiate mammary tumours in BR6 mice.
The hormones of early pregnancy were occasionally sufficient stimulus for the
regrowth ofregressed tumours, as indicated by those few tumours which resumed
growth about the time of maximal luteal activity on days 7 and 8 (Forbes and
Hooker, 1957). Twelve outof21 regressedtumoursrecurredfollowing one or more
pseudopregnancies but only one ofthese displayed hormone dependency. Foulds
(1949b) observedonly 1 brieftumourrecurrence amongst 8pseudopregnant females.
There may be strain differences in the importance of ovarian hormones in
tumour production. Although pseudopregnancies were not sufficient to promote
the development of new tumours in BR6 mice, Law (1941) found that pseudo-
pregnancies increasedthetumourincidenceinnon-parous A strainmicefrom 5% to
26%. Marchant (1963) reported that susceptibility to mammary tumour induc-
tion by methylcholanthrene was increased in some lines of mice by pseudo-
pregnancies.
Itseemsthereforethatforinitialtumour development, thehormones (placental,
pituitary or ovarian) oflate pregnancy are necessary. The minimal length oftime
these factors are required cannot be ascertained until a reliable and non-traumatic
method ofterminating pregnancies at any specific time is found.
The action of5HT is not clear, but Meites, Talwalker and Nicoll (1960) reported
that it stimulated mammary gland growth and lactation in oestrogen-primed rats
and rabbits, probably by impairing the normal hypothalamic inhibitory control of
prolactin secretion. In that case, the luteotrophic action of the excess prolactin
should be shown by the replacement ofnormal oestrous cycles with long periods of
di-oestrus (Miihlbock and Boot, 1959). However, a group of virgin mice showed
no significant difference in the proportions ofoestrous vaginal smears seen during a
control period and during 5HT treatment (unpublished observations). Lindsay,
Poulson and Robson (1963) found that the lethal effects of5HT on mouse embryos
during the first half of gestation, could be overcome by the administration of
progesterone or prolactin. They suggested that 5HT was not causing hyper-
secretion ofprolactin in their animals.
It has also been reported that 5HT stimulates the release of ACTH in rats
(Smelik andde Wied, 1958; Miyawaki, UiaiidKobayashi, 1961)andthismechanism
too might influence tumour development.
The influence of 5HT in BR6 mice was marginal, as oestrous cycles were not
significantly altered in the same way as they were by almost continuous prolactin
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secretion from an ectopic pituitary (Muhlbock and Boot, 1959) and 5HT did not
alter the tumour incidence in virgin mice. Nevertheless it had some enhancing
effect on tumour development when given to breeding females.
Subsequent studies have attempted to reproduce the endocrine conditions
required for the de novo appearance of tumours (Lee, 1970).
I would like to thank Dr. L. Martin and Mr. P. C. Williams for their helpful
comments and advice, and Miss J. K. Warren for skilled technical assistance.
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